Glück Conviction Score™ ⓘ
AGIO
AGIOS PHARMACEUTICALS, INC.
Effektiv: Neutral
Mittel
Bedeutung der Einstufung ⓘ
Insider
0,0
Keine Insider-Käufe
Institutionell
50,5
32 neu, 79 erhöht, 435,3M $ netto
Aktivist
23,6
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,69% (Stand: 31.05.2026)
Score-Verlauf (90 Tage)
Farbzonen = Stärkestufen (Sehr schwach … Sehr stark). Exit-Score unter der Schwelle = Timing-Ausstieg. Komponenten per Legende einblenden.
Kursverlauf (12 Monate)
Technische Indikatoren
Technical-Score basiert auf 12 Indikatoren (Trend, Momentum, Volatilität, Position) mit fixen Gewichten — wird aktuell nur informativ angezeigt und fließt nicht in den Glück Conviction Score ein. Integration nach Backtest-Kalibrierung (P5).
| Indikator | Signal | Gewicht | Wert | Detail | Beitrag |
|---|---|---|---|---|---|
| Kurs vs SMA50 | Bullisch | 10 % | 29.19 | +0.9 % vs SMA50 | |
| Kurs vs SMA200 | Bärisch | 15 % | 31.85 | -7.5 % vs SMA200 | |
| EMA20 vs EMA50 | Bärisch | 5 % | 28.45 | EMA50: 28.69 | |
| MACD-Histogramm | Bullisch | 10 % | 0.133 | Bullisch | |
| RSI(14) | Neutral | 10 % | 55.0 | Neutral (30–70) | |
| Stoch %K(14) | Neutral | 5 % | 73.8 | Neutral | |
| ADX(14)+DI | Neutral | 10 % | 9.9 | +DI: 26.1 / −DI: 18.1 | |
| Z-Score(60) | Neutral | 5 % | 0.06 | In Range | |
| 52W-Position | Neutral | 5 % | 30.8 % | Hoch 45.49 / Tief 22.34 | |
| Bollinger(20,2σ) | Bärisch | 5 % | 82.8 % | Upper 30.01 / Mid 28.41 / Lower 26.81 | |
| LinReg-Slope(60) | Neutral | 10 % | -0.0637 | R²=0.16 / annualisiert -54.8 % |
Insider-Transaktionen (12 Monate) ⓘ
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-02 | Jones Cecilia | Officer, Chief Financial Officer | Open Market Sale | -3.141 | 34,71 | -109.024,11 | -94,3% | |
| 2026-04-02 | Viswanadhan Krishnan | Officer, Chief Corp Dev & Strategy | Open Market Sale | -2.959 | 34,71 | -102.706,89 | -88,9% | |
| 2026-04-02 | Burns James William | Officer, Chief Legal Officer | Open Market Sale | -3.280 | 34,71 | -113.848,80 | -98,5% | |
| 2026-04-02 | Goff Brian | Director, Officer, Chief Executive Officer | Open Market Sale | -12.472 | 34,71 | -432.903,12 | -374,6% | |
| 2026-04-02 | Goff Brian | Director, Officer, Chief Executive Officer | Open Market Sale | -6.596 | 34,71 | -228.947,16 | -198,1% | |
| 2026-04-02 | Milanova Tsveta | Officer, Chief Commercial Officer | Open Market Sale | -3.262 | 34,71 | -113.224,02 | -98,0% | |
| 2026-04-02 | Gheuens Sarah | Officer, Chief Medical Officer | Open Market Sale | -2.940 | 34,71 | -102.047,40 | -88,3% | |
| 2026-03-05 | Viswanadhan Krishnan | Officer, Chief Corp Dev & Strategy | Open Market Sale | -2.959 | 27,80 | -82.260,20 | -71,2% | |
| 2026-03-03 | Washburn Theodore James Jr. | Officer, Principal Accounting Officer | Open Market Sale | -5.272 | 28,88 | -152.255,36 | -131,8% | |
| 2026-03-02 | Jones Cecilia | Officer, Chief Financial Officer | Open Market Sale | -594 | 28,96 | -17.202,24 | -14,9% | |
| 2026-03-02 | Gheuens Sarah | Officer, Chief Medical Officer | Open Market Sale | -1.681 | 28,96 | -48.681,76 | -42,1% | |
| 2026-03-02 | Gheuens Sarah | Officer, Chief Medical Officer | Open Market Sale | -1.187 | 28,96 | -34.375,52 | -29,7% | |
| 2026-03-02 | Burns James William | Officer, Chief Legal Officer | Open Market Sale | -1.681 | 28,96 | -48.681,76 | -42,1% | |
| 2026-03-02 | Burns James William | Officer, Chief Legal Officer | Open Market Sale | -1.187 | 28,96 | -34.375,52 | -29,7% | |
| 2026-03-02 | Burns James William | Officer, Chief Legal Officer | Open Market Sale | -1.163 | 28,96 | -33.680,48 | -29,1% | |
| 2026-03-02 | Washburn Theodore James Jr. | Officer, Principal Accounting Officer | Open Market Sale | -798 | 28,96 | -23.110,08 | -20,0% | |
| 2026-03-02 | Washburn Theodore James Jr. | Officer, Principal Accounting Officer | Open Market Sale | -698 | 28,96 | -20.214,08 | -17,5% | |
| 2026-03-02 | Washburn Theodore James Jr. | Officer, Principal Accounting Officer | Open Market Sale | -727 | 28,96 | -21.053,92 | -18,2% | |
| 2026-03-02 | Goff Brian | Director, Officer, Chief Executive Officer | Open Market Sale | -8.267 | 28,96 | -239.412,32 | -207,2% | |
| 2026-03-02 | Goff Brian | Director, Officer, Chief Executive Officer | Open Market Sale | -5.918 | 28,96 | -171.385,28 | -148,3% | |
| 2026-03-02 | Goff Brian | Director, Officer, Chief Executive Officer | Open Market Sale | -3.870 | 28,96 | -112.075,20 | -97,0% | |
| 2026-03-02 | Milanova Tsveta | Officer, Chief Commercial Officer | Open Market Sale | -1.681 | 28,96 | -48.681,76 | -42,1% | |
| 2026-03-02 | Milanova Tsveta | Officer, Chief Commercial Officer | Open Market Sale | -1.187 | 28,96 | -34.375,52 | -29,7% | |
| 2026-03-02 | Jones Cecilia | Officer, Chief Financial Officer | Open Market Sale | -1.681 | 28,96 | -48.681,76 | -42,1% | |
| 2026-03-02 | Jones Cecilia | Officer, Chief Financial Officer | Open Market Sale | -1.573 | 28,96 | -45.554,08 | -39,4% | |
| 2026-03-02 | Jones Cecilia | Officer, Chief Financial Officer | Open Market Sale | -1.187 | 28,96 | -34.375,52 | -29,7% | |
| 2026-01-05 | Milanova Tsveta | Officer, Chief Commercial Officer | Open Market Sale | -2.872 | 27,02 | -77.601,44 | -67,2% | |
| 2025-12-30 | Milanova Tsveta | Officer, Chief Commercial Officer | Open Market Sale | -2.932 | 27,09 | -79.427,88 | -68,7% | |
| 2025-12-30 | Goff Brian | Director, Officer, Chief Executive Officer | Open Market Sale | -12.473 | 27,09 | -337.893,57 | -292,4% | |
| 2025-12-30 | Goff Brian | Director, Officer, Chief Executive Officer | Open Market Sale | -6.230 | 27,09 | -168.770,70 | -146,0% | |
| 2025-12-30 | Burns James William | Officer, Chief Legal Officer | Open Market Sale | -2.932 | 27,09 | -79.427,88 | -68,7% | |
| 2025-12-30 | Gheuens Sarah | Officer, Chief Medical Officer | Open Market Sale | -2.932 | 27,09 | -79.427,88 | -68,7% | |
| 2025-12-30 | Jones Cecilia | Officer, Chief Financial Officer | Open Market Sale | -2.932 | 27,09 | -79.427,88 | -68,7% | |
| 2025-11-12 | Scadden David | Director | Open Market Sale | -200 | 43,84 | -8.768,00 | -7,6% | |
| 2025-11-11 | Gheuens Sarah | Officer, Chief Medical Officer | Open Market Sale | -2.454 | 43,78 | -107.436,12 | -93,0% | |
| 2025-10-30 | Gheuens Sarah | Officer, Chief Medical Officer | Open Market Sale | -200 | 43,81 | -8.762,00 | -7,6% | |
| 2025-10-27 | Gheuens Sarah | Officer, Chief Medical Officer | Open Market Sale | -3.302 | 43,92 | -145.023,84 | -125,5% | |
| 2025-10-08 | Scadden David | Director | Open Market Sale | -200 | 41,00 | -8.200,00 | -7,1% | |
| 2025-09-30 | Scadden David | Director | Open Market Sale | -200 | 40,00 | -8.000,00 | -6,9% | |
| 2025-09-26 | Jones Cecilia | Officer, Chief Financial Officer | Open Market Sale | -3.651 | 36,77 | -134.247,27 | -116,2% | |
| 2025-09-05 | Washburn Theodore James Jr. | Officer, Principal Accounting Officer | Open Market Sale | -8.546 | 36,87 | -315.091,02 | -272,7% | |
| 2025-08-27 | Scadden David | Director | Open Market Sale | -200 | 40,00 | -8.000,00 | -6,9% | |
| 2025-08-08 | Goff Brian | Director, Officer, Chief Executive Officer | Open Market Sale | -11.085 | 36,67 | -406.486,95 | -351,7% | |
| 2025-07-10 | Scadden David | Director | Open Market Sale | -1.400 | 40,00 | -56.000,00 | -48,5% | |
| 2025-07-09 | Gheuens Sarah | Officer, Chief Medical Officer | Open Market Sale | -847 | 38,76 | -32.829,72 | -28,4% | |
| 2025-07-09 | Gheuens Sarah | Officer, Chief Medical Officer | Open Market Sale | -11.067 | 37,93 | -419.771,31 | -363,2% | |
| 2025-07-01 | Gheuens Sarah | Officer, Chief Medical Officer | Open Market Sale | -4.091 | 34,17 | -139.789,47 | -121,0% | |
| 2025-06-24 | Burns James William | Officer, Chief Legal Officer | Open Market Sale | -2.799 | 33,54 | -93.878,46 | -81,2% | |
| 2025-06-24 | Goff Brian | Director, Officer, Chief Executive Officer | Open Market Sale | -12.471 | 33,54 | -418.277,34 | -362,0% | |
| 2025-06-24 | Goff Brian | Director, Officer, Chief Executive Officer | Open Market Sale | -6.229 | 33,54 | -208.920,66 | -180,8% | |
| 2025-06-24 | Milanova Tsveta | Officer, Chief Commercial Officer | Open Market Sale | -2.770 | 33,54 | -92.905,80 | -80,4% | |
| 2025-06-24 | Gheuens Sarah | Officer, Chief Medical Officer | Open Market Sale | -2.909 | 33,54 | -97.567,86 | -84,4% | |
| 2025-06-24 | Jones Cecilia | Officer, Chief Financial Officer | Open Market Sale | -1.780 | 33,54 | -59.701,20 | -51,7% |
Fondsaktivität (Vorquartalsvergleich) ⓘ
| Fonds | Aktuell (Stk) | Vorquartal (Stk) | Veränderung (Stk) | Wert (USD) | Status | Δ | Trend |
|---|---|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC | 5.916.000 | 6.036.000 | -120.000 | 200.138.280 | Reduziert | -2,0% | |
| BlackRock, Inc. | 5.754.957 | 5.235.429 | 519.528 | 194.690.195 | Aufgestockt | +9,9% | |
| FARALLON CAPITAL MANAGEMENT LLC | 5.684.000 | 0 | 5.684.000 | 192.289.720 | Neu | +100,0% | |
| VANGUARD GROUP INC | 5.594.353 | 0 | 5.594.353 | 152.278.288 | Neu | +100,0% | |
| STATE STREET CORP | 3.364.879 | 3.108.145 | 256.734 | 113.719.376 | Aufgestockt | +8,3% | |
| D. E. Shaw & Co., Inc. | 2.681.169 | 1.861.286 | 819.883 | 90.703.947 | Aufgestockt | +44,0% | |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.632.316 | 0 | 2.632.316 | 89.051.250 | Neu | +100,0% | |
| Lynx1 Capital Management LP | 2.611.568 | 79.624 | 2.531.944 | 88.349.345 | Aufgestockt | +3179,9% | |
| Erste Asset Management GmbH | 2.704.900 | 2.804.900 | -100.000 | 80.092.089 | Reduziert | -3,6% | |
| BNP Paribas Asset Management Holding S.A. | 1.580.840 | 1.360.730 | 220.110 | 53.479.817 | Aufgestockt | +16,2% | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1.556.353 | 2.882.332 | -1.325.979 | 52.651.422 | Reduziert | -46,0% | |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 1.494.435 | 1.701.409 | -206.974 | 50.557.000 | Reduziert | -12,2% | |
| GEODE CAPITAL MANAGEMENT, LLC | 1.467.910 | 1.413.538 | 54.372 | 49.670.160 | Aufgestockt | +3,8% | |
| MPM BioImpact LLC | 1.306.261 | 1.303.373 | 2.888 | 44.190.810 | Aufgestockt | +0,2% | |
| Frazier Life Sciences Management, L.P. | 1.256.080 | 1.279.754 | -23.674 | 42.493.186 | Reduziert | -1,8% | |
| DIMENSIONAL FUND ADVISORS LP | 1.151.614 | 1.004.341 | 147.273 | 38.940.060 | Aufgestockt | +14,7% | |
| MORGAN STANLEY | 967.525 | 894.037 | 73.488 | 32.731.410 | Aufgestockt | +8,2% | |
| TCG Crossover Management, LLC | 1.181.841 | 0 | 1.181.841 | 32.169.712 | Neu | +100,0% | |
| JANE STREET GROUP, LLC | 841.440 | 1.449.150 | -607.710 | 28.465.915 | Reduziert | -41,9% | |
| GOLDMAN SACHS GROUP INC | 817.676 | 1.033.974 | -216.298 | 27.661.979 | Reduziert | -20,9% | |
| Rock Springs Capital Management LP | 799.163 | 799.163 | 0 | 27.035.684 | Unverändert | 0,0% | |
| CITADEL ADVISORS LLC | 769.413 | 1.608.868 | -839.455 | 26.029.242 | Reduziert | -52,2% | |
| Nuveen, LLC | 722.348 | 297.908 | 424.440 | 24.437.033 | Aufgestockt | +142,5% | |
| WELLINGTON MANAGEMENT GROUP LLP | 641.486 | 597.826 | 43.660 | 21.701.472 | Aufgestockt | +7,3% | |
| SCS Capital Management LLC | 612.850 | 598.765 | 14.085 | 20.732.716 | Aufgestockt | +2,4% | |
| Foresite Capital Management VI LLC | 525.000 | 530.000 | -5.000 | 17.760.750 | Reduziert | -0,9% | |
| NORTHERN TRUST CORP | 509.272 | 511.901 | -2.629 | 17.228.672 | Reduziert | -0,5% | |
| BANK OF AMERICA CORP /DE/ | 507.900 | 539.341 | -31.441 | 17.182.243 | Reduziert | -5,8% | |
| Artisan Partners Limited Partnership | 481.516 | 504.485 | -22.969 | 16.289.686 | Reduziert | -4,6% | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 477.032 | 482.622 | -5.590 | 16.137.993 | Reduziert | -1,2% | |
| Connor, Clark & Lunn Investment Management Ltd. | 450.093 | 562.642 | -112.549 | 15.226.646 | Reduziert | -20,0% | |
| Vestal Point Capital, LP | 450.000 | 325.000 | 125.000 | 15.223.500 | Aufgestockt | +38,5% | |
| MARSHALL WACE, LLP | 448.118 | 353.639 | 94.479 | 15.159.832 | Aufgestockt | +26,7% | |
| Legal & General Group Plc | 423.915 | 328.211 | 95.704 | 14.341.046 | Aufgestockt | +29,2% | |
| ArrowMark Colorado Holdings LLC | 403.590 | 466.151 | -62.561 | 13.653.450 | Reduziert | -13,4% | |
| Parkman Healthcare Partners LLC | 403.525 | 99.604 | 303.921 | 13.651.251 | Aufgestockt | +305,1% | |
| GROUP ONE TRADING LLC | 330.479 | 563.214 | -232.735 | 11.180.105 | Reduziert | -41,3% | |
| BNP PARIBAS FINANCIAL MARKETS | 327.457 | 242.670 | 84.787 | 11.077.870 | Aufgestockt | +34,9% | |
| KENNEDY CAPITAL MANAGEMENT LLC | 275.456 | 65.655 | 209.801 | 9.318.676 | Aufgestockt | +319,6% | |
| TWO SIGMA INVESTMENTS, LP | 251.636 | 300.156 | -48.520 | 8.512.846 | Reduziert | -16,2% | |
| JPMORGAN CHASE & CO | 312.077 | 0 | 312.077 | 8.494.735 | Neu | +100,0% | |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 250.461 | 0 | 250.461 | 8.473.096 | Neu | +100,0% | |
| PANAGORA ASSET MANAGEMENT INC | 238.468 | 79.840 | 158.628 | 8.067.372 | Aufgestockt | +198,7% | |
| Palo Alto Investors LP | 213.601 | 212.499 | 1.102 | 7.226.122 | Aufgestockt | +0,5% | |
| Seven Fleet Capital Management LP | 209.547 | 31.738 | 177.809 | 7.088.975 | Aufgestockt | +560,2% | |
| Squarepoint Ops LLC | 208.888 | 121.763 | 87.125 | 7.066.681 | Aufgestockt | +71,6% | |
| Ikarian Capital, LLC | 252.689 | 0 | 252.689 | 6.878.195 | Neu | +100,0% | |
| Schonfeld Strategic Advisors LLC | 200.061 | 0 | 200.061 | 6.768.062 | Neu | +100,0% | |
| Eversept Partners, LP | 200.000 | 0 | 200.000 | 6.766.000 | Neu | +100,0% | |
| Qube Research & Technologies Ltd | 187.667 | 378.373 | -190.706 | 6.348.775 | Reduziert | -50,4% |
Top-Fondshalter (Stand: 31.03.2026) ⓘ
| Fonds | Anteile | Vorquartal (Stk) | Δ | Wert (USD) | Anteil (%) |
|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC | 5.916.000 | 6.036.000 | -2,0% | 200.138.280 | 9,87 |
| BlackRock, Inc. | 5.754.957 | 5.235.429 | +9,9% | 194.690.195 | 9,60 |
| FARALLON CAPITAL MANAGEMENT LLC | 5.684.000 | 0 | +100,0% | 192.289.720 | 9,48 |
| STATE STREET CORP | 3.364.879 | 3.108.145 | +8,3% | 113.719.376 | 5,61 |
| D. E. Shaw & Co., Inc. | 2.681.169 | 1.861.286 | +44,0% | 90.703.947 | 4,47 |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.632.316 | 0 | +100,0% | 89.051.250 | 4,39 |
| Lynx1 Capital Management LP | 2.611.568 | 79.624 | +3179,9% | 88.349.345 | 4,36 |
| Erste Asset Management GmbH | 2.704.900 | 2.804.900 | -3,6% | 80.092.089 | 3,95 |
| BNP Paribas Asset Management Holding S.A. | 1.580.840 | 1.360.730 | +16,2% | 53.479.817 | 2,64 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1.556.353 | 2.882.332 | -46,0% | 52.651.422 | 2,60 |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 1.494.435 | 1.701.409 | -12,2% | 50.557.000 | 2,49 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.467.910 | 1.413.538 | +3,8% | 49.670.160 | 2,45 |
| MPM BioImpact LLC | 1.306.261 | 1.303.373 | +0,2% | 44.190.810 | 2,18 |
| Frazier Life Sciences Management, L.P. | 1.256.080 | 1.279.754 | -1,8% | 42.493.186 | 2,10 |
| DIMENSIONAL FUND ADVISORS LP | 1.151.614 | 1.004.341 | +14,7% | 38.940.060 | 1,92 |
| MORGAN STANLEY | 967.525 | 894.037 | +8,2% | 32.731.410 | 1,61 |
| JANE STREET GROUP, LLC | 841.440 | 1.449.150 | -41,9% | 28.465.915 | 1,40 |
| GOLDMAN SACHS GROUP INC | 817.676 | 1.033.974 | -20,9% | 27.661.979 | 1,36 |
| Rock Springs Capital Management LP | 799.163 | 799.163 | 0,0% | 27.035.684 | 1,33 |
| CITADEL ADVISORS LLC | 769.413 | 1.608.868 | -52,2% | 26.029.242 | 1,28 |
Halter-Trend (6 Quartale)
| Periode | Status | Halter | Anteile (Mio) | Wert (Mio $) |
|---|---|---|---|---|
| 31.03.2026 | ✓ | 233 | 70,1 | 2.233 |
| 31.12.2025 | ✓ | 237 | 70,0 | 1.792 |
| 30.09.2025 | ✓ | 231 | 75,4 | 2.875 |
| 30.06.2025 | ✓ | 216 | 62,6 | 1.921 |
| 31.03.2025 | ✓ | 217 | 65,1 | 1.774 |
| 31.12.2024 | ✓ | 221 | 63,1 | 1.913 |
Top 10 Neueinsteiger
| Fonds | Anteile | Wert (USD) ⓘ |
|---|---|---|
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 1.701.409 | 46.312.000 |
| MPM BioImpact LLC | 1.303.373 | 35.477.813 |
| Capital International Investors | 703.865 | 19.159.205 |
| Foresite Capital Management VI LLC | 530.000 | 14.426.600 |
| Qube Research & Technologies Ltd | 378.373 | 10.299.313 |
| Trexquant Investment LP | 226.600 | 6.168.052 |
| Edgestream Partners, L.P. | 167.998 | 4.572.906 |
| Tetragon Partners GP Ltd | 162.018 | 4.410.130 |
| Exome Asset Management LLC | 136.942 | 3.727.561 |
| Squarepoint Ops LLC | 121.763 | 3.314.389 |
Top 10 Aufstocker
| Fonds | Anteile | Δ Anteile ⓘ | Δ % ⓘ | Wert (USD) ⓘ |
|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC | 6.036.000 | 4.372.000 | +262.7 % | 164.299.920 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 2.882.332 | 2.447.432 | +562.8 % | 78.457.077 |
| D. E. Shaw & Co., Inc. | 1.861.286 | 1.493.537 | +406.1 % | 50.664.205 |
| CITADEL ADVISORS LLC | 1.608.868 | 1.003.886 | +165.9 % | 43.793.387 |
| JANE STREET GROUP, LLC | 1.449.150 | 986.030 | +212.9 % | 39.445.863 |
| STATE STREET CORP | 3.108.145 | 845.433 | +37.4 % | 84.603.707 |
| BlackRock, Inc. | 5.235.429 | 689.691 | +15.2 % | 142.508.377 |
| GROUP ONE TRADING LLC | 563.214 | 515.514 | +1080.7 % | 15.330.685 |
| MORGAN STANLEY | 894.037 | 477.039 | +114.4 % | 24.335.710 |
| MILLENNIUM MANAGEMENT LLC | 418.267 | 413.218 | +8184.2 % | 11.385.228 |
Top 10 Verkäufer
| Fonds | Anteile | Δ Anteile ⓘ | Δ % ⓘ | Wert (USD) ⓘ |
|---|---|---|---|---|
| Caligan Partners LP | 90.000 | -2.016.205 | -95.7 % | 2.449.800 |
| WELLINGTON MANAGEMENT GROUP LLP | 597.826 | -1.873.590 | -75.8 % | 16.272.823 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 637.886 | -1.019.052 | -61.5 % | 17.364 |
| DEUTSCHE BANK AG\ | 122.875 | -803.859 | -86.7 % | 3.344.658 |
| BOOTHBAY FUND MANAGEMENT, LLC | 104.491 | -736.150 | -87.6 % | 2.844.245 |
| BANK OF AMERICA CORP /DE/ | 539.341 | -590.659 | -52.3 % | 14.680.852 |
| TCG Crossover Management, LLC | 1.181.841 | -248.200 | -17.4 % | 32.169.712 |
| ArrowMark Colorado Holdings LLC | 466.151 | -213.771 | -31.4 % | 12.688.630 |
| Caption Management, LLC | 227.686 | -206.408 | -47.5 % | 6.197.613 |
| Rock Springs Capital Management LP | 799.163 | -159.379 | -16.6 % | 21.753.217 |
Aktivisten & Großaktionäre (13D/13G) ⓘ
| Datum | Investor | Typ | Anteil | Aktien | Δ | Zweck |
|---|---|---|---|---|---|---|
| 15.05.2026 | Armistice Capital, LLC | Passiv (13G/A) | 4,57 % | 2.716.000 | -0,64 pp | |
| 15.05.2026 | Steven Boyd | Passiv (13G/A) | 4,57 % | 2.716.000 | -0,64 pp | |
| 06.05.2026 | Weston Nichols | Passiv (13G) | 5,10 % | 3.013.949 | Neu | |
| 06.05.2026 | Lynx1 Capital Management LP | Passiv (13G) | 5,10 % | 3.013.949 | Neu | |
| 29.04.2026 | Vanguard Capital Management | Passiv (13G) | 5,27 % | 3.088.169 | Neu | |
| 26.03.2026 | The Vanguard Group | Passiv (13G/A) | Ausstieg | 0 | -10,02 pp | |
| 17.02.2026 | Steven Boyd | Passiv (13G) | 5,21 % | 3.036.000 | +1,33 pp | |
| 17.02.2026 | Armistice Capital, LLC | Passiv (13G) | 5,21 % | 3.036.000 | +1,33 pp | |
| 09.02.2026 | Short Daniel S. | Passiv (13G/A) | 8,80 % | 5.159.505 | -1,10 pp | |
| 09.02.2026 | Farallon Capital Institutional Partners II, L.P. | Passiv (13G/A) | 0,20 % | 136.781 | 0,00 pp | |
| 09.02.2026 | Farallon Healthcare Partners (GP), L.L.C. | Passiv (13G/A) | 5,00 % | 2.928.459 | -0,80 pp | |
| 09.02.2026 | Farallon Institutional (GP) V, L.L.C. | Passiv (13G/A) | 0,20 % | 97.883 | 0,00 pp | |
| 09.02.2026 | Roberts, Jr., Thomas G. | Passiv (13G/A) | 8,80 % | 5.159.505 | -1,10 pp | |
| 09.02.2026 | Spokes, Andrew J. M. | Passiv (13G/A) | 8,80 % | 5.159.505 | -1,10 pp | |
| 09.02.2026 | Wehrly, Mark C. | Passiv (13G/A) | 8,80 % | 5.159.505 | -1,10 pp | |
| 09.02.2026 | Linn, Michael G. | Passiv (13G/A) | 8,80 % | 5.159.505 | -1,10 pp | |
| 09.02.2026 | Farallon Capital Institutional Partners III, L.P. | Passiv (13G/A) | 0,10 % | 56.489 | 0,00 pp | |
| 09.02.2026 | Luo Patrick (Cheng) | Passiv (13G/A) | 8,80 % | 5.159.505 | -1,10 pp | |
| 09.02.2026 | Saito Edric C. | Passiv (13G/A) | 8,80 % | 5.159.505 | -1,10 pp | |
| 09.02.2026 | Farallon Capital Partners, L.P. | Passiv (13G/A) | 0,70 % | 413.359 | 0,00 pp | |
| 09.02.2026 | Giauque, Nicolas | Passiv (13G/A) | 8,80 % | 5.159.505 | -1,10 pp | |
| 09.02.2026 | Farallon F5 (GP), L.L.C. | Passiv (13G/A) | 0,20 % | 113.104 | -0,20 pp | |
| 09.02.2026 | Fried, Richard B | Passiv (13G/A) | Ausstieg | 0 | -9,90 pp | |
| 09.02.2026 | Husen, Avner A. | Passiv (13G/A) | 8,80 % | 5.159.505 | Neu | |
| 09.02.2026 | Kim, David T. | Passiv (13G/A) | 8,80 % | 5.159.505 | -1,10 pp | |
| 09.02.2026 | Farallon Partners, L.L.C. | Passiv (13G/A) | 8,70 % | 5.046.401 | -0,90 pp | |
| 09.02.2026 | Patel, Rajiv A. | Passiv (13G/A) | Ausstieg | 0 | -9,90 pp | |
| 09.02.2026 | Seybold, William | Passiv (13G/A) | Ausstieg | 0 | -9,90 pp | |
| 09.02.2026 | Farallon Healthcare Partners Master, L.P. | Passiv (13G/A) | 5,00 % | 2.928.459 | -0,80 pp | |
| 09.02.2026 | Farallon Capital F5 Master I, L.P. | Passiv (13G/A) | 0,20 % | 113.104 | -0,20 pp | |
| 09.02.2026 | Warren, John R. | Passiv (13G/A) | 8,80 % | 5.159.505 | -1,10 pp | |
| 09.02.2026 | Dapice Joshua J. | Passiv (13G/A) | 8,80 % | 5.159.505 | -1,10 pp | |
| 09.02.2026 | Farallon Capital Institutional Partners, L.P. | Passiv (13G/A) | 0,80 % | 446.450 | 0,00 pp | |
| 09.02.2026 | Farallon Capital (AM) Investors, L.P. | Passiv (13G/A) | 0,10 % | 62.455 | 0,00 pp | |
| 09.02.2026 | Farallon Capital Offshore Investors II, L.P. | Passiv (13G/A) | 1,60 % | 904.525 | +0,10 pp | |
| 09.02.2026 | Four Crossings Institutional Partners V, L.P. | Passiv (13G/A) | 0,20 % | 97.883 | 0,00 pp | |
| 09.02.2026 | Dreyfuss, Philip D. | Passiv (13G/A) | 8,80 % | 5.159.505 | -1,10 pp | |
| 09.02.2026 | Gehani, Varun N. | Passiv (13G/A) | 8,80 % | 5.159.505 | -1,10 pp | |
| 09.02.2026 | Dunn Hannah E. | Passiv (13G/A) | 8,80 % | 5.159.505 | -1,10 pp | |
| 09.02.2026 | STATE STREET CORPORATION | Passiv (13G) | 5,30 % | 3.108.145 | Neu |
US Congress Trades (STOCK Act)
| Datum | Mitglied | Partei | Kammer | Typ | Betrag-Bereich |
|---|---|---|---|---|---|
| 03.03.2026 | Gilbert Cisneros | – | House | Kauf | $1,001 – $15,000 |
| 11.12.2025 | Gilbert Cisneros | – | House | Kauf | $1,001 – $15,000 |
| 17.04.2025 | Gilbert Cisneros | – | House | Kauf | $1,001 – $15,000 |
| 29.01.2025 | Gilbert Cisneros | – | House | Kauf | $1,001 – $15,000 |
Quelle: House eFD & Senate eFD (STOCK Act PTR). Betragsangaben sind Bereichsangaben — keine Exaktwerte. Tiefenanalyse für diese Aktie → · Alle Kongress-Bestände →
Stammdaten
Agios Pharmaceuticals, Inc., ein biopharmazeutisches Unternehmen, ist in der Entdeckung und Entwicklung von Arzneimitteln im Bereich des Zellstoffwechsels und angrenzender Biologiebereiche tätig. Das Unternehmen bietet PYRUKYND (Mitapivat), einen Aktivator von Wild-Typ- und verschiedenen mutanten Pyruvatkinase-PK-Enzymen zur Behandlung von hämolytischen Anämien an, sowie AG-946, das sich in Phase-I-Klinischer Studie zur Behandlung von hämolytischen Anämien und anderen Indikationen befindet. Agios Pharmaceuticals, Inc. wurde 2007 gegründet und hat seinen Sitz in Cambridge, Massachusetts.
Unternehmen & Branche
| Name | AGIOS PHARMACEUTICALS, INC. |
|---|---|
| Ticker | AGIO |
| CIK | 0001439222 |
| Boerse | Nasdaq |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | 00847X104 |
|---|---|
| ISIN | US00847X1046 |
| Typ | Common Stock |
| Marktkapitalisierung | 1,68 Mrd. USD |
| Beta | 0,58 |
Bewertung
| KBV (P/B) | 1,41 vs. 1,38 (2021) ▲ |
|---|---|
| KUV (P/S) | 31,04 |
| FCF-Rendite | -22,5 % vs. -23,1 % (2021) ▲ |
Qualität & Bilanz
| Bruttomarge | 88,3 % |
|---|---|
| Operative Marge | -873,9 % |
| Nettomarge | -764,0 % |
| ROIC | -33,5 % vs. 115,5 % (2021) ▼ |
Basis: SEC-XBRL-Jahresabschluss bis 31.12.2025, Multiples mit aktueller Marktkapitalisierung (trailing), Vergleich: GJ bis 2021. Kennzahlen erklärt →
Kennzahlen-Historie (5 Jahre) – Tabelle & Verlauf
| Kennzahl | 2021 | 2022 | 2023 | 2024 | 2025 | Verlauf |
|---|---|---|---|---|---|---|
| Bewertung | ||||||
| KBV (P/B) | 1,38 | 1,40 | 1,54 | 1,22 | 1,33 | |
| KUV (P/S) | – | 108,53 | 46,45 | 51,46 | 29,45 | |
| FCF-Rendite | -23,1 % | -20,3 % | -23,8 % | -20,8 % | -23,7 % | |
| Qualität & Bilanz | ||||||
| Bruttomarge | – | 88,0 % | 89,3 % | 88,6 % | 88,3 % | |
| Operative Marge | – | -2.732,1 % | -1.459,5 % | -1.166,5 % | -873,9 % | |
| Nettomarge | – | -1.627,8 % | -1.312,6 % | 1.845,9 % | -764,0 % | |
| ROIC | 115,5 % | -19,5 % | -39,9 % | 42,2 % | -33,5 % | |
Basis: SEC-XBRL-Jahresabschlüsse, Multiples je Geschäftsjahr mit Marktkapitalisierung zum Bilanzstichtag (point-in-time).
Externe Quelle:
SEC EDGAR »
Externe Links: Yahoo Finance » · OnVista »
Finanzkennzahlen (SEC XBRL) ⓘ
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2026-03-31 | 10-Q | 20.746.000 | -99.111.000 | -1,69 | 1.184.990.000 | 1.109.115.000 |
| 2025-12-31 | 10-K | 54.028.000 | -412.781.000 | -7,12 | 1.297.225.000 | 1.193.114.000 |
| 2025-09-30 | 10-Q | 12.880.000 | -103.433.000 | -1,78 | 1.385.705.000 | 1.284.330.000 |
| 2025-06-30 | 10-Q | 12.455.000 | -112.020.000 | -1,93 | 1.471.237.000 | 1.369.555.000 |
| 2025-03-31 | 10-Q | 8.726.000 | -89.289.000 | -1,55 | 1.555.518.000 | 1.466.528.000 |
| 2024-12-31 | 10-K | 36.498.000 | 673.725.000 | 11,64 | 1.663.199.000 | 1.540.956.000 |
| 2024-09-30 | 10-Q | 8.964.000 | 947.915.000 | 16,22 | 1.791.794.000 | 1.626.672.000 |
| 2024-06-30 | 10-Q | 8.615.000 | -96.118.000 | -1,69 | 773.063.000 | 660.510.000 |
| 2024-03-31 | 10-Q | 8.189.000 | -81.549.000 | -1,45 | 849.709.000 | 743.922.000 |
| 2023-12-31 | 10-K | 26.823.000 | -352.088.000 | -6,33 | 937.118.000 | 811.019.000 |
| 2023-09-30 | 10-Q | 7.399.000 | -91.324.000 | -1,64 | 1.007.258.000 | 886.843.000 |
| 2023-06-30 | 10-Q | 6.712.000 | -83.806.000 | -1,51 | 1.085.153.000 | 964.236.000 |
| 2023-03-31 | 10-Q | 5.609.000 | -81.018.000 | -1,47 | 1.151.298.000 | 1.036.526.000 |
| 2022-12-31 | 10-K | 14.240.000 | -231.801.000 | -4,23 | 1.238.718.000 | 1.100.814.000 |
| 2022-09-30 | 10-Q | 3.516.000 | -81.747.000 | -1,49 | 1.180.320.000 | 1.050.170.000 |
| 2022-06-30 | 10-Q | 5.582.000 | -91.806.000 | -1,68 | 1.252.467.000 | 1.124.070.000 |
| 2022-03-31 | 10-Q | 832.000 | -94.774.000 | -1,74 | 1.335.859.000 | 1.207.453.000 |
| 2021-12-31 | 10-K | 0 | 1.604.715.000 | 26,55 | 1.437.736.000 | 1.291.975.000 |
| 2021-09-30 | 10-Q | 0 | -88.766.000 | -1,56 | 1.541.498.000 | 1.394.762.000 |
| 2021-06-30 | 10-Q | 0 | -86.217.000 | -1,41 | 1.874.603.000 | 1.721.816.000 |
Umsatz nach Segmenten & Regionen ⓘ
Geschäftssegmente
| Segment | FY 2025 | FY 2024 | FY 2023 | FY 2022 | Anteil | Δ | Trend |
|---|---|---|---|---|---|---|---|
| Product | 54,0 Mio. | 36,5 Mio. | 26,8 Mio. | 11,7 Mio. | 100,0 % | +48,0% | |
| Royalty | – | – | – | 2,5 Mio. | – | – |
Quartalsergebnisse (Earnings) ⓘ
| Quartal | Stichtag | Verkündet | Umsatz | EPS |
|---|---|---|---|---|
| Q1 2026 | 31.03.2026 | 29.04.2026 | 20,7 Mio. USD | -1,69 |
| Q3 2025 | 30.09.2025 | 30.10.2025 | 12,9 Mio. USD | -1,78 |
| Q2 2025 | 30.06.2025 | 30.10.2025 | 12,5 Mio. USD | -1,93 |
| Q1 2025 | 31.03.2025 | 29.04.2026 | 8,7 Mio. USD | -1,55 |
| Q3 2024 | 30.09.2024 | 30.10.2025 | 9,0 Mio. USD | 16,22 |
| Q2 2024 | 30.06.2024 | 30.10.2025 | 8,6 Mio. USD | -1,69 |
| Q1 2024 | 31.03.2024 | 30.10.2025 | 8,2 Mio. USD | -1,45 |
| Q3 2023 | 30.09.2023 | 31.10.2024 | 7,4 Mio. USD | -1,64 |
| Q2 2023 | 30.06.2023 | 31.10.2024 | 6,7 Mio. USD | -1,51 |
Einreichungs-Historie (10-K / 10-Q)
SEC-Einreichungs-Historie der Quartalsberichte (10-Q) und Jahresberichte
(10-K) der letzten sechs Jahre. Die Spalte „Verzögerung" zeigt die
Tage zwischen Berichtsstichtag und tatsächlicher Einreichung.
Suffix /A kennzeichnet nachträgliche Berichtigungen.
| Eingereicht | Form | Berichtsperiode | Verzögerung | |
|---|---|---|---|---|
| 29.04.2026 | 10-Q | – | – | SEC » |
| 12.02.2026 | 10-K | 31.12.2025 | 43 Tage | SEC » |
| 30.10.2025 | 10-Q | 30.09.2025 | 30 Tage | SEC » |
| 31.07.2025 | 10-Q | 30.06.2025 | 31 Tage | SEC » |
| 01.05.2025 | 10-Q | 31.03.2025 | 31 Tage | SEC » |
| 13.02.2025 | 10-K | 31.12.2024 | 44 Tage | SEC » |
| 31.10.2024 | 10-Q | 30.09.2024 | 31 Tage | SEC » |
| 01.08.2024 | 10-Q | 30.06.2024 | 32 Tage | SEC » |
| 02.05.2024 | 10-Q | 31.03.2024 | 32 Tage | SEC » |
| 15.02.2024 | 10-K | 31.12.2023 | 46 Tage | SEC » |
| 02.11.2023 | 10-Q | 30.09.2023 | 33 Tage | SEC » |
| 03.08.2023 | 10-Q | 30.06.2023 | 34 Tage | SEC » |
| 04.05.2023 | 10-Q | 31.03.2023 | 34 Tage | SEC » |
| 23.02.2023 | 10-K | 31.12.2022 | 54 Tage | SEC » |
| 03.11.2022 | 10-Q | 30.09.2022 | 34 Tage | SEC » |
| 04.08.2022 | 10-Q | 30.06.2022 | 35 Tage | SEC » |
| 05.05.2022 | 10-Q | 31.03.2022 | 35 Tage | SEC » |
| 24.02.2022 | 10-K | 31.12.2021 | 55 Tage | SEC » |
| 03.11.2021 | 10-Q | 30.09.2021 | 34 Tage | SEC » |
| 29.07.2021 | 10-Q | 30.06.2021 | 29 Tage | SEC » |
| 07.05.2021 | 10-Q/A | 31.03.2021 | 37 Tage | SEC » |
| 29.04.2021 | 10-Q | 31.03.2021 | 29 Tage | SEC » |
| 25.02.2021 | 10-K | 31.12.2020 | 56 Tage | SEC » |
| 05.11.2020 | 10-Q | 30.09.2020 | 36 Tage | SEC » |
| 30.07.2020 | 10-Q | 30.06.2020 | 30 Tage | SEC » |
Filing-Analyse (10-K / 10-Q)
Narrative-Analyse der letzten Quartals-/Jahresberichte durch Claude (nur Coverage-Gruppen-Mitglieder). Keine Anlageberatung — der qualitative Score dient der Einordnung, nicht als Kaufempfehlung; siehe allgemeiner Hinweis am Seitenende.
| Datum | Form | Stimmung | Guidance | Qualitativ | Zusammenfassung | |
|---|---|---|---|---|---|---|
| 12.02.2026 | 10-K | 0,15 | ↑ | 52,0 | Agios erhielt im Dezember 2025 die FDA-Zulassung für AQVESME™ (Mitapivat) in der Thalassämie-Indikation und startete den kommerziellen Launc… | |
|
Zusammenfassung: Agios erhielt im Dezember 2025 die FDA-Zulassung für AQVESME™ (Mitapivat) in der Thalassämie-Indikation und startete den kommerziellen Launch Ende Januar 2026; gleichzeitig wurde ein positives CHMP-Votum der EMA für dieselbe Indikation erreicht. Die Phase-3-Studie RISE UP in Sichelzellkrankheit erfüllte den primären Hämoglobin-Endpunkt (p<0,0001), verfehlte jedoch den zweiten Ko-primären Endpunkt (SCPC-Rate, p=0,1213), was den Zulassungsweg in dieser Indikation mit Unsicherheit belastet. Operativ verbrennt das Unternehmen weiterhin erhebliche Mittel (Nettverlust 2025: ~413 Mio. USD bei nur 54 Mio. USD Produktumsatz), verfügt aber über eine solide Liquiditätsreserve von 1,2 Mrd. USD und erwartet 2026 mehrere relevante Datentoplines aus dem Pipeline-Portfolio. Bis zur operativen Profitabilität bleibt der Weg lang und hängt maßgeblich von einer erfolgreichen AQVESME™-Marktdurchdringung und weiteren Zulassungen ab. Guidance-Zitate:
|
||||||
Kritische 8-K Meldungen ⓘ
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 08.07.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment… |
Fail-to-Deliver (6 Monate) ⓘ
| Datum | FTD-Menge | Kurs | Wert (USD) |
|---|---|---|---|
| 2026-04-30 | 367 | 28,05 | 10.294 |
| 2026-04-20 | 8.600 | 35,14 | 302.204 |
| 2026-04-15 | 120 | 33,30 | 3.996 |
| 2026-04-08 | 3.517 | 35,11 | 123.482 |
| 2026-03-04 | 79 | 28,48 | 2.250 |
| 2026-02-19 | 381 | 27,56 | 10.500 |
| 2026-01-13 | 148 | 28,32 | 4.191 |
| 2025-12-30 | 37 | 27,16 | 1.005 |
| 2025-12-22 | 6.382 | 24,46 | 156.104 |
| 2025-12-17 | 100 | 26,09 | 2.609 |